Declan Doogan Biography and Net Worth

Director of Tenax Therapeutics

Dr. Declan Doogan joined the Board in February 2021. He has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the U.S., the U.K. and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Since November 2019, Dr. Doogan has served as co-founder and Chief Medical Officer of Juvenescence Ltd., a life sciences company developing therapies to modify aging and increase healthy human lifespan. From June 2013 to May 2019, Dr. Doogan served as Chief Executive Officer of Portage Biotech, Inc. (Nasdaq: PRTG), a clinical-stage immuno-oncology company, where he currently remains a director. Declan is also an investor in emerging biotechnology and technology companies, and is a partner at Mediqventures Ltd., a biotech merchant bank and investment firm. Dr. Doogan currently serves as a member of the board of directors of Apterna Ltd. and Causeway Therapeutics Ltd. Dr. Doogan previously served as chairman of the board of directors of Biohaven Pharmaceuticals (NYSE: BHVN) and a member of the boards of directors of Intensity Therapeutics, Inc. (NASDAQ: INTS), Sosei Group Corporation (TSE: 4565), Kleo Pharmaceuticals, Inc. and Celleron Therapeutics Ltd. He has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the U.K.

What is Declan Doogan's net worth?: The estimated net worth of Declan Doogan is at least $106.40 thousand as of September 16th, 2026. Doogan owns 55,274 shares of Tenax Therapeutics stock worth more than $106,402 as of September 18th. This net worth approximation does not reflect any other assets that Doogan may own. Learn More about Declan Doogan's net worth.
How do I contact Declan Doogan?: The corporate mailing address for Doogan and other Tenax Therapeutics executives is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, 27517. Tenax Therapeutics can also be reached via phone at 919-855-2100 and via email at [email protected]. Learn More on Declan Doogan's contact information.
Has Declan Doogan been buying or selling shares of Tenax Therapeutics?: Within the last three months, Declan Doogan has bought $101,760.00 of Tenax Therapeutics stock. Most recently, on Wednesday, September 16th, Declan Doogan bought 53,000 shares of Tenax Therapeutics stock. The stock was acquired at an average cost of $1.92 per share, with a total value of $101,760.00. Following the completion of the transaction, the director now directly owns 55,274 shares of the company's stock, valued at $106,126.08. Learn More on Declan Doogan's trading history.
Who are Tenax Therapeutics' active insiders?: Tenax Therapeutics' insider roster includes Declan Doogan (Director), Christopher Giordano (President and Chief Executive Officer), and Stuart Rich (CHIEF MEDICAL OFFICER). Learn More on Tenax Therapeutics' active insiders.
Are insiders buying or selling shares of Tenax Therapeutics?: In the last twelve months, Tenax Therapeutics insiders bought shares 19 times. They purchased a total of 2,778,155 shares worth more than $5,071,142.51. The most recent insider tranaction occured on September, 16th when Director Declan Doogan bought 53,000 shares worth more than $101,760.00. Insiders at Tenax Therapeutics own 10.8% of the company. Learn More about insider trades at Tenax Therapeutics.
Information on this page was last updated on 9/16/2026.

Declan Doogan Insider Trading History at Tenax Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2026	Buy	53,000	$1.92	$101,760.00	55,274

Declan Doogan Buying and Selling Activity at Tenax Therapeutics

Tenax Therapeutics Company Overview

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Today's Range

Now: $1.91

$1.85

$1.97

50 Day Range

MA: $7.37

$1.38

$17.55

2 Week Range

Now: $1.91

$1.31

$19.40

Volume

3,838,033 shs

Average Volume

2,208,161 shs

Market Capitalization

$71.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83